Ampio Pharmaceuticals appoints new CFO
This article was originally published in Scrip
US-based Ampio Pharmaceuticals has named Mark McGregor chief financial officer and corporate secretary. Bruce Miller, who has served in these roles since April 2010, will join the team that will advance the commercialisation of Ampio's Phase III product candidate, Zertane, which was obtained through the acquisition of DMI BioSciences in 2010. Mr Miller had served as DMI's chief executive officer and/or president since 1992. Ampio is developing proprietary drugs for metabolic, eye and kidney diseases, inflammation, CNS disease and male sexual dysfunction.